SCHEMBL3345116

SCHEMBL3345116

O=C1O[C]1c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
ALDH1A1 P00352 2/20 0.47
ALOX15 P16050 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CTRC Q99895 3/20 0.42
CFTR P13569 1/20 0.42
GOPC Q9HD26 1/20 0.42
KDM4E B2RXH2 1/20 0.42
PLA2G10 O15496 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KMT2A Q03164 1/20 0.41
PTGS2 P35354 1/20 0.40
BACE1 P56817 1/20 0.40
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PARP1 P09874 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL592300 0.73 PTGS2 (0.65) MAPTLMNAHTTALDH1A1ALOX15
Benzene SCHEMBL28277789 0.73 BACE1 (0.50) MAPTLMNAHTTALDH1A1ALOX15
SCHEMBL210321 0.73 BACE1 (0.50) MAPTLMNAHTTALDH1A1ALOX15
Biphenyl SCHEMBL1627414 0.71 ALDH1A1 (0.90) MAPTLMNAHTTALDH1A1TDP1
Biphenyl SCHEMBL11779109 0.71 ALDH1A1 (0.90) MAPTLMNAHTTALDH1A1TDP1
SCHEMBL10736364 0.71 PTGS2 (0.69) MAPTLMNAHTTALDH1A1ALOX15
Biphenyl SCHEMBL1930656 0.71 ALDH1A1 (0.50) MAPTLMNAHTTALDH1A1ALOX15
Biphenyl SCHEMBL28187670 0.71 TDP1 (0.78) MAPTLMNAHTTALDH1A1ALOX15
Biphenyl SCHEMBL1458263 0.69 ALDH1A1 (0.69) MAPTLMNAHTTALDH1A1TDP1
SCHEMBL22795388 0.67 ALDH1A1 (0.53) MAPTLMNAHTTALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3894416-A1 FERROPORTIN INHIBITORS AND METHODS OF USE Global Blood Therapeutics, Inc. (US) 2021-10-20 EP disclosed
WO-2020123850-A1 FERROPORTIN INHIBITORS AND METHODS OF USE GLOBAL BLOOD THERAPEUTICS, INC. (US) 2020-06-18 WO disclosed
US-10035889-B2 Optical film MITSUI CHEMICALS, INC. (JP) 2018-07-31 US disclosed
US-20160032063-A1 Optical Film KEIO UNIVERSITY (JP) 2016-02-04 US disclosed
EP-2838927-A2 SULFONIUM COMPOUNDS, THEIR PREPARATION AND USE BASF SE (DE) 2015-02-25 EP disclosed
WO-2013156509-A2 SULFONIUM COMPOUNDS, THEIR PREPARATION AND USE BASF SE (DE) 2013-10-24 WO disclosed
WO-2008154207-A9 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-04-22 WO disclosed
US-7635775-B2 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
WO-2008154207-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2008-12-18 WO disclosed
US-20060293332-A1 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2006-12-28 US disclosed
WO-2005100334-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITORS PFIZER PRODUCTS INC. (US) 2005-10-27 WO disclosed
WO-2004013128-A1 NOVEL SUBSTITUTED BENZAMIDES PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM (DE) 2004-02-12 WO disclosed
EP-0385287-A2 Process for the preparation of D-mannosamine derivatives FORSCHUNGSZENTRUM JÜLICH GMBH (DE) 1990-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293332-A1 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists BDKRB2, BDKRB1, PDXK MAPT 4721/4885LMNA 1723/4885HTT 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.